Barr, Reisner to Chair PLI’s Developments in
Pharma and Biotech Patent Law 2016
1177 Avenue of Americas (2nd floor)
New York, NY 10036 December 9, 2016 PLI California Seminar Center
685 Market Street
San Francisco, CA 94105
Intellectual Property partners David Barr and Daniel Reisner will chair Practising Law Institute’s Developments in Pharmaceutical and Biotech Patent Law 2016 CLE program on November 9, 2016 in New York City and December 9, 2016 in San Francisco, respectively.
In addition to chairing the program, both partners will give presentations addressing technological innovation, Federal Circuit appellate oversight and Supreme Court decisions that continue to drive significant changes in pharmaceutical and biotech patent law. Barr will present “Biosimilar Developments” to show how to navigate the intricacies of the biosimilar approval process, provide strategies for addressing exclusivity and patent issues, and review recent litigation under the Biologics Price Competition and Innovation Act. Reisner’s “Willfulness: A Return to the Bad Old Days” revisits willfulness law in biotech and Hatch-Waxman cases in view of the high court’s recent Halo v. Pulse decision.
Barr and Reisner are recognized thought leaders in the pharma and biotech areas. Both partners are the co-editors and co-authors of the eighth edition of PLI’s well-received and highly referenced Pharmaceutical and Biotech Patent Law treatise, which was published in June 2016. The treatise, which was considered a “home run” when first published and is currently viewed as “a great addition to the library of any legal or business practitioner in the field, as well as for any government office,” provides the legal, scientific and technical information needed to help clients obtain, defend and challenge patents in these important business areas.